Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 1.00 |
| ▸ | RARA | P10276 | 16/20 | 1.00 |
| ▸ | RARG | P13631 | 13/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757231 | 0.91 | RARA (1.00) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6240286 | 0.90 | RARB (0.81) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL14020999 | 0.89 | RARB (0.80) | RARBRARARARG | |
| SCHEMBL8981775 | 0.88 | RARA (0.82) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL27463415 | 0.88 | RARA (0.78) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6237886 | 0.88 | RARA (1.00) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6238148 | 0.88 | RARB (0.77) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL8771827 | 0.88 | RARA (0.78) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6234835 | 0.87 | RARA (0.81) | RARBRARARARG | |
| SCHEMBL6232866 | 0.87 | RARA (0.77) | RARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0661259-B1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL MYERS SQUIBB CO (US) | 1997-10-08 | — | — | EP | claimed |
| US-5618839-A | Retinoid-like compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | claimed |
| EP-0661259-A1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-05 | — | — | EP | claimed |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115671292-A | Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy | IO治疗公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-109310763-B | Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy | IO治疗公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-0991636-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | Allergan Sales, Inc. (US) | 2000-04-12 | — | — | EP | disclosed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0661259-B1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL MYERS SQUIBB CO (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5648385-A | TREATING RHEUMATOID ARTHRITIS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5618839-A | Retinoid-like compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0661259-A1 | Substituted (5,6)-dihydronaphthalenyl compounds having retinoid-like activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARB 5/4885RARA 6/4885RARG 4/4885 |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RARB 5/4885RARA 6/4885RARG 4/4885 |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RARB 5/4885RARA 6/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.